Abstract
Breast Cancer is one of the main neoplasia that affect women and the second largest cause of mortality in the world, the advance for early diagnosis can be with the use of Radiopharmaceutical FES-18F, because it has affinity for the Estrogen Receptor present in 75 % of breast cancer cases being possible for non-invasive diagnosis and follow-up of the patient. For the FES-18F synthesis, a …